The Modified Fatigue Impact Scale (MFIS) and the Beck Depression Inventory-II (BDI-II) scores are independent risk factors for disability that are unrelated to relapse in multiple sclerosis (MS). This finding is based on a new study by researchers in Spain, which assessed patients’ perspectives in clinical practice.

The researchers reported that all patient-reported outcome measures that they analyzed were changed in people with MS. Despite this, MFIS was the only measure that could discriminate between current and progressive disability, thereby identifying MS patients whose disease is at risk of progressing. 

The study is published in the journal Scientific Reports.


Continue Reading

Read more about the different types of MS

The observational study included 116 patients with MS. Of these, 30 had progressive MS, while the remaining 86 had relapsing MS. Researchers investigated disability progression after 2 years of follow-up in all patients. 

They found that patient-reported outcomes could differentiate between people with progressive and relapsing MS, with those with relapsing disease having lower scores on the MS quality of life scales and higher scores on the MFIS and BDI-II scales.

The researchers reported that only MFIS scores were correlated with disability in people with relapsing MS, with high scores in the physical domain of the scale being associated with worse performance in the 9-Hole Peg Test, and trends in the timed 25-Foot Walk and the Symbol Digit Modalities tests.

On the other hand, the cognitive domain of the MFIS was correlated with the levels of chitinase 3–like 1 in the cerebrospinal fluid, which is a biomarker of progression. 

“In conclusion, in this report we show that the information gathered from people with MS provides useful information about their current status, as a snapshot, but also might predict the course of the disease,” the researchers wrote.

Reference

Gil-Perotin S, Bernad L, Reddam S, et al. Patient’s perspective in clinical practice to assess and predict disability in multiple sclerosis. Sci Rep. Published online October 29, 2022. doi:10.1038/s41598-022-23088-x